Search Results - "SHAW, WAYNE"

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial by Neal, Bruce, PhD, Perkovic, Vlado, PhD, de Zeeuw, Dick, PhD, Mahaffey, Kenneth W., MD, Fulcher, Greg, MD, Stein, Peter, MD, Desai, Mehul, MD, Shaw, Wayne, DSL, Jiang, Joel, PhD, Vercruysse, Frank, MD, Meininger, Gary, MD, Matthews, David, DPhil

“…Sodium glucose co-transporter 2 inhibition is a novel mode of treatment for type 2 diabetes mellitus (T2DM). The sodium glucose co-transporter 2 inhibitor…”
Get full text

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial by Neal, Bruce, Perkovic, Vlado, Matthews, David R., Mahaffey, Kenneth W., Fulcher, Greg, Meininger, Gary, Erondu, Ngozi, Desai, Mehul, Shaw, Wayne, Vercruysse, Frank, Yee, Jacqueline, Deng, Hsiaowei, de Zeeuw, Dick

“…Aims The primary aim of the CANagliflozin cardioVascular Assessment Study‐Renal (CANVAS‐R) is to determine whether the favourable effects of inhibition of the…”
Get full text

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus by Rosenthal, Norm, Meininger, Gary, Ways, Kirk, Polidori, David, Desai, Mehul, Qiu, Rong, Alba, Maria, Vercruysse, Frank, Balis, Dainius, Shaw, Wayne, Edwards, Robert, Bull, Scott, Di Prospero, Nicholas, Sha, Sue, Rothenberg, Paul, Canovatchel, William, Demarest, Keith

“…The sodium glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin is a novel treatment option for adults with type 2 diabetes mellitus (T2DM). In patients…”
Get full text

Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial by Sen, Taha, Li, Jingwei, Neuen, Brendon L, Arnott, Clare, Neal, Bruce, Perkovic, Vlado, Mahaffey, Kenneth W, Shaw, Wayne, Canovatchel, William, Hansen, Michael K, Heerspink, Hiddo J L

“…Background Studies have suggested that sodium glucose co-transporter 2 inhibitors exert anti-inflammatory effects. We examined the association of baseline…”
Get full text

Effects of Canagliflozin on Amino-Terminal Pro–B-Type Natriuretic Peptide by Januzzi, James L., Xu, Jialin, Li, JingWei, Shaw, Wayne, Oh, Richard, Pfeifer, Michael, Butler, Javed, Sattar, Naveed, Mahaffey, Kenneth W., Neal, Bruce, Hansen, Michael K.

Get full text

Why do firms switch underwriters? by Krigman, Laurie, Shaw, Wayne H, Womack, Kent L

“…In the mid-1990s, 30% of firms completing an SEO within three years of their IPO switched lead underwriter. This article provides evidence on why they…”
Get full text

The Effect of Regulation and Financial Distress on Banks' Auditor Fees by Shaw, Wayne H., Terando, William D.

“…The purpose of this article is to provide a comparison of the impact on audit pricing of the Sarbanes–Oxley Act of 2002 to that of the 2008 financial collapse…”
Get full text

Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies by Gilbert, Richard E., MD, PhD, FRCPC, Weir, Matthew R., MD, Fioretto, Paola, MD, PhD, Law, Gordon, PhD, Desai, Mehul, MD, Kline, Irina, MD, Shaw, Wayne, DSL, Meininger, Gary, MD

“…Abstract Objective Reduced efficacy has been reported in the elderly; it may be a consequence of an age-dependent decline in estimated glomerular filtration…”
Get full text

The Persistence of IPO Mispricing and the Predictive Power of Flipping by Krigman, Laurie, Shaw, Wayne H., Womack, Kent L.

“…This paper examines underwriters' pricing errors and the information content of first-day trading activity in IPOs. We show that first-day winners continue to…”
Get full text

The Pricing of Initial Public Offerings: Tests of Adverse-Selection and Signaling Theories by Michaely, Roni, Shaw, Wayne H.

“…We test the empirical implications of several models of IPO underpricing. Consistent with the winner's-curse hypothesis, we show that in markets where…”
Get full text

The impact of accounting rule and economic differences on the firm’s choice of cash and share-puts by Terando, William D., Shaw, Wayne H., Smith, David B., Gary, Robert F.

“…While prior literature has sought to explain why firms issue put options on their own stock (Gibson et al., 2006), no one has focused on examining why some…”
Get full text

Deposit Insurance and Wealth Effects: The Value of Being "Too Big to Fail" by O'Hara, Maureen, Shaw, Wayne

Get full text

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes by Neal, Bruce, Perkovic, Vlado, Mahaffey, Kenneth W, de Zeeuw, Dick, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Law, Gordon, Desai, Mehul, Matthews, David R

“…In this report of two randomized trials, patients with type 2 diabetes at risk for cardiovascular disease received the sodium–glucose cotransporter 2 inhibitor…”
Get full text

Valuation of the Components of Purchased Goodwill by Henning, Steven L., Lewis, Barry L., Shaw, Wayne H.

“…This paper examines whether investors distinguish among identifiable components of goodwill for valuation purposes, in the year of acquisition. Similar to…”
Get full text

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study) by Mahaffey, Kenneth W, Neal, Bruce, Perkovic, Vlado, de Zeeuw, Dick, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Fabbrini, Elisa, Sun, Tao, Li, Qiang, Desai, Mehul, Matthews, David R

“…BACKGROUND:Canagliflozin is a sodium glucose cotransporter 2 inhibitor that significantly reduces the composite of cardiovascular death, nonfatal myocardial…”
Get full text

Valuation and classification of company issued cash and share-puts by Terando, William D, Shaw, Wayne H, Smith, David B

“…This paper examines whether investors' valuations of cash and share-put warrants are influenced by their potential differential effect on firm solvency. It is…”
Get full text

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials by Perkovic, Vlado, de Zeeuw, Dick, Mahaffey, Kenneth W, Fulcher, Greg, Erondu, Ngozi, Shaw, Wayne, Barrett, Terrance D, Weidner-Wells, Michele, Deng, Hsiaowei, Matthews, David R, Neal, Bruce

“…In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, canagliflozin reduced the rates of major adverse cardiovascular events and the results…”
Get full text

The Amount and Timing of Goodwill Write-Offs and Revaluations: Evidence from U.S. and U.K. Firms by Henning, Steven L, Shaw, Wayne H, Stock, Toby

“…This paper investigates criticisms that U.S. GAAP had given firms too much discretion in determining the amount and timing of goodwill write-offs. Using 1,576…”
Get full text

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program by Rådholm, Karin, Figtree, Gemma, Perkovic, Vlado, Solomon, Scott D, Mahaffey, Kenneth W, de Zeeuw, Dick, Fulcher, Greg, Barrett, Terrance D, Shaw, Wayne, Desai, Mehul, Matthews, David R, Neal, Bruce

“…BACKGROUND:Canagliflozin is a sodium glucose cotransporter 2 inhibitor that reduces the risk of cardiovascular events. We report the effects on heart failure…”
Get full text

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program by Figtree, Gemma A, Rådholm, Karin, Barrett, Terrance D, Perkovic, Vlado, Mahaffey, Kenneth W, de Zeeuw, Dick, Fulcher, Greg, Matthews, David R, Shaw, Wayne, Neal, Bruce

Get full text